Rhinoplasty and Other Nasal Procedures (for Idaho Only)
This policy governs medical necessity and coverage criteria for rhinoplasty and other nasal procedures for members in Idaho, including Idaho Medicaid Plus plans. It specifies reconstructive indications, unproven procedures, definitions, and applicable CPT/HCPCS codes.
New Medical Policy established.
Coverage Criteria and Clinical Selection
inv-01: Nasal valve procedures — medically necessary
Covered when ALL of the following are met
inv-02: Rhinophyma excision — medically necessary
Covered when ALL of the following are met
inv-03: Rhinoplasty — congenital anomalies
Covered when the following are present
inv-04: Rhinoplasty-primary — medically necessary
Covered when ALL of the following are met
inv-05: Rhinoplasty-revision — medically necessary
Covered when ALL of the following are met
inv-06: Rhinoplasty-tip — medically necessary
Covered when ALL of the following are met
inv-07: Nasal polypectomy — criteria via InterQual
Covered when criteria per external InterQual referenced are met
inv-08: Criteria for coverage of nasal valve repair and absorbable implant use
Covered when ALL of the following are met
inv-09: Device-based lateral wall support (Latera) — study-based selection
Absorbable lateral wall implant (Latera) considered in patients when ALL of the following match study populations:
inv-10: Nasal Septal Swell Body reduction — study-based selection
NSB (septal swell body) reduction considered when ALL of the following are met as per available studies:
inv-11: Posterior nasal nerve / SPG ablation — trial-based selection
PNN or SPG ablation (cryoablation or TCRF) considered when ALL of the following are met in line with RCT inclusion criteria:
inv-12: Clinical evidence synthesis
Evidence and guideline context relevant to coverage determinations
inv-13: Eligibility — PNN ablation
Typical eligibility elements observed in clinical studies
inv-14: Eligibility — nasal valve TCRF
Typical eligibility for nasal valve TCRF (VivAer) procedures
inv-15: Device treatment clinical evidence
Clinical evidence considered for device-based treatments of nasal valve/NAO:
Procedures that do not meet the specific reconstructive criteria described for nasal valve repair, rhinophyma excision, rhinoplasty (primary, revision, or tip), and related indicated interventions are not considered reconstructive and medically necessary. Examples include cases lacking documented mechanical nasal airway obstruction, absence of required photographic documentation of dynamic collapse or anatomic deformity, missing description of whether compromise is static or dynamic and which valve(s) are involved, or no clear surgical plan (including need for cartilage graft) correlating the deformity to obstruction.
The following devices and procedures are described in the policy text as unproven or not medically necessary due to insufficient evidence of safety and/or efficacy: absorbable polylactic acid nasal cartilage support implants (e.g., Latera), nasal septal swell body (NSB) reduction procedures (e.g., VivAer when used for septal swell body), posterior nasal nerve (PNN) or sphenopalatine ganglion (SPG) ablation using any method (including radiofrequency devices such as RhinAer or cryoablation devices such as ClariFix), and radiofrequency treatment of nasal valves (e.g., VivAer ARC Stylus). Available manufacturer descriptions and evidence summaries note promising results but emphasize low-quality studies, limited long-term follow-up, and need for randomized comparative trials.
Procedures performed solely for cosmetic purposes that do not preserve or enhance nasal airway function are excluded from consideration as reconstructive rhinoplasty. Rhinoplasty and adjunctive nasal procedures are considered reconstructive only when the procedure is intended to correct an anatomic mechanical nasal airway obstruction and documentation (including photographs) demonstrates the functional indication.
The evidence base for many of the device- and procedure-based interventions is limited by short follow-up durations, small sample sizes, single-arm designs, and potential industry sponsorship. Systematic reviews and evolving evidence assessments note that available studies often lack parallel control groups, have heterogeneous populations and techniques, and provide inadequate long‑term outcome data beyond 12–24 months.
Procedures that lack adequate controlled evidence, long‑term outcomes, or well‑conducted comparative trials are considered unsupported by the current evidence in this excerpt. In particular, single-arm case series without controls and studies at higher risk of bias do not establish comparative effectiveness for PNN/SPG ablation or absorbable nasal implants.
FDA clearance or 510(k) status is provided for informational context only and is not by itself a basis for coverage decisions. Device regulatory information (for example, VivAer Stylus 510(k) clearance and classification details) does not replace the need for clinical evidence demonstrating safety and effectiveness for covered indications.
This policy excerpt references several specific devices and procedures in summary: absorbable lateral wall implants (Latera) for lateral wall support, temperature‑controlled radiofrequency devices (VivAer) for nasal valve remodeling or septal swell body reduction, and neuroablative devices (RhinAer, ClariFix) for posterior nasal nerve or SPG ablation. These are cited as examples of technologies reviewed in the evidence summaries.
Use of absorbable implants should not be offered as a simple substitute for established functional rhinoplasty techniques without documentation that the implant is clinically indicated and that less‑invasive or standard reconstructive options (e.g., cartilage grafting, open repair) are inappropriate. Providers must document the rationale for implant versus traditional surgery and that implant use is intended to stabilize the lateral nasal wall for a mechanical nasal airway obstruction.
Evidence limitations noted across studies include lack of randomized, long‑term comparative data; small or single‑center cohorts; allowance of adjunctive procedures that confound outcomes; and variability in objective measurement tools. These limitations should be considered when interpreting study conclusions and when evaluating requests for coverage of novel devices or techniques.
Where the published evidence is minimal or provides unclear guidance—such as for certain cryoablation or radiofrequency procedures and some implant applications—the policy highlights that conclusions about effectiveness are tentative and that higher‑quality comparative trials with longer follow-up are needed before definitive coverage determinations can be made.
The excerpt does not always include explicit statements labeling interventions as "not medically necessary" for every context; however, absence of robust evidence (short follow-up, uncontrolled designs, or inconsistent outcomes) implies that payers may consider such procedures unsupported pending stronger comparative data and documentation that patient selection matches studied populations.
Applicable Procedure and Device Codes
| 30117 | Excision or destruction (e.g., laser) of intranasal lesion; internal approach. |
| 30120 | Excision or surgical planing of skin of nose for rhinophyma. |
| 30400 | Rhinoplasty, primary; lateral and alar cartilages and/or elevation of nasal tip. |
| 30410 | Rhinoplasty, primary; complete, external parts including bony pyramid, lateral and alar cartilages, and/or elevation of nasal tip. |
| 30420 | Rhinoplasty, primary; including major septal repair. |
| 30430 | Rhinoplasty, secondary; minor revision (small amount of nasal tip work). |
| 30435 | Rhinoplasty, secondary; intermediate revision (bony work with osteotomies). |
| 30450 | Rhinoplasty, secondary; major revision (nasal tip work and osteotomies). |
| 30460 | Rhinoplasty for nasal deformity secondary to congenital cleft lip and/or palate, including columellar lengthening; tip only. |
| 30462 | Rhinoplasty for nasal deformity secondary to congenital cleft lip and/or palate, including columellar lengthening; tip, septum, osteotomies. |
| 30999 | Unlisted procedure, nose. |
| 31237 | Nasal/sinus endoscopy, surgical; with biopsy, polypectomy or debridement (separate procedure). |
| 31242 | Nasal/sinus endoscopy, surgical; with destruction by radiofrequency ablation, posterior nasal nerve. |
| 31243 | Nasal/sinus endoscopy, surgical; with destruction by cryoablation, posterior nasal nerve. |
| 64999 | Unlisted procedure, nervous system. |
| L8699 | Prosthetic implant, not otherwise specified. |
| No codes listed |
| Latera | Bioabsorbable lateral wall implant (brand name referenced) |
| VivAer | Temperature-controlled radiofrequency device for septal swell body reduction (brand name referenced) |
| ClariFix | Cryotherapy device for posterior nasal nerve ablation (brand name referenced) |
| RhinAer | Device for temperature-controlled radiofrequency neurolysis of the PNN (brand name referenced) |
| LRC | Product code: instrument, ENT, manual surgical (device classification) |
| LYA | Product code: intranasal septal splint devices (Class I) |
Prior Authorization, Documentation, and Billing Guidance
Coding review / Prior authorization
All nasal surgical claims may be subject to coding review. Prior authorization is recommended/required per the member's plan. Providers should verify plan-specific prior authorization rules before scheduling procedures.
Clinical selection and documentation for prior authorization
Prior authorization decisions depend on thorough clinical selection and documentation demonstrating that nasal valve compromise or other anatomic causes are the primary driver of nasal airway obstruction and that conservative measures and other causes have been addressed.
- Clearly state whether compromise is static or dynamic and whether internal valve, external valve, or both are involved.
- Describe the planned surgical approach and any need for cartilage grafts or implants.
Prior authorization — eligibility evidence
Prior authorization requests should include objective and subjective eligibility evidence showing the member meets reconstructive criteria and that other causes have been treated.
- Documentation that other causes of nasal obstruction (rhinosinusitis, allergic rhinitis, polyps, adenoid hypertrophy, nasopharyngeal masses) were adequately treated.
- Evidence that septal deviation and turbinate hypertrophy are not present, previously treated, or planned for simultaneous correction.
Prior authorization and plan requirements
Authorization is plan- and contract-specific. Verify member benefits, medical necessity requirements, and any InterQual or third-party criteria used by UnitedHealthcare for administration.
- Check the member's contract for cosmetic vs reconstructive distinctions and any prior authorization pathways.
- Where applicable, InterQual or other evidence-based tools may be applied.
Denial triggers — Unproven procedures
Procedures identified in the policy as unproven should be considered not medically necessary and may be denied when submitted for those indications.
- Absorbable polylactic acid nasal implants (e.g., Latera) for some indications — evidence limited; policy lists as unproven where specified.
- Nasal septal swell body (NSB) reduction and posterior nasal nerve/sphenopalatine ganglion ablation may be considered unproven for certain indications per policy.
Potential coverage rationale
Some procedures may be covered when reconstructive criteria are clearly met; otherwise, they may be considered cosmetic and denied. Coverage rationale depends on whether the procedure corrects an anatomic mechanical airway obstruction and whether conservative management failed.
- Reconstructive coverage may be supported when prolonged obstructed breathing is documented, other causes treated, photos and exam findings demonstrate the anatomic cause, and conservative management failed.
- Procedures performed primarily for aesthetic reasons without functional impairment are typically considered cosmetic and not covered.
Evidence limitations may affect coverage
Limitations in the evidence base for newer devices and minimally invasive procedures may impact coverage decisions — favorable short-term results do not substitute for long-term comparative data.
- Studies often are single-arm, industry-sponsored, or lack adequate control groups and long-term follow-up.
- Device regulatory clearance (e.g., 510(k)) is informational and does not by itself establish coverage.
Evidence limitations may trigger denial
When evidence limitations are present or required reconstructive criteria are not met, prior authorization may be denied. Denials may also arise when documentation is incomplete or when conservative therapy requirements are not satisfied.
- Denial triggers include: lack of photos demonstrating dynamic collapse, absence of documented modified Cottle maneuver improvement, missing description of valve involvement, or failure to document prior conservative therapy.
- Denials may follow when procedures are listed as unproven or experimental for the submitted indication.
Required clinical documentation (photographs, dynamic collapse exam)
Provide complete clinical documentation with the prior authorization submission: history, focused physical exam, objective and subjective measures, and supportive photographs or video of dynamic collapse where applicable.
- Preoperative photographs that clearly document dynamic collapse or anatomic deformity consistent with exam.
- Documentation of modified Cottle maneuver with subjective/audible improvement in airflow.
Required clinical documentation elements — baseline symptom scores and indication
Prior authorization submissions should include baseline symptom scores, responder definitions, and documentation that conservative management was attempted and failed.
- Baseline NOSE or rTNSS scores and follow-up/responder thresholds where available (e.g., ≥20% NOSE improvement or defined MCID used in studies).
- Documentation of at least 4 weeks of conservative management when specified (e.g., nasal steroids, immunotherapy) or other trial durations used in evidence summaries.
Background and Rationale
Mechanical nasal airway obstruction is difficulty breathing through the nose due to bony or cartilaginous deformity. Nasal valve collapse may be static or dynamic and frequently requires surgical support or grafting for definitive stabilization. Clinical evaluation should document the anatomic site of collapse and correlate photographs and exam findings with functional symptoms to support reconstructive treatment decisions.
Definitions
Revision History
New medical policy established and made effective.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.